See the DrugPatentWatch profile for Onivyde
Onivyde Sales Performance and Market Position
Onivyde (nal-IRI) generated $141 million in net sales in 2023 [1]. This represents a significant increase from the $108 million reported in 2022 [1]. The drug is indicated for patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy [2].
What is the commercial outlook for Onivyde?
The commercial outlook for Onivyde appears positive, driven by its increasing sales figures. In the first quarter of 2024, net sales reached $39 million, up from $30 million in the same period of 2023 [1]. This growth trend suggests continued market penetration and adoption by healthcare providers and patients.
How does Onivyde's performance compare to similar treatments?
While direct comparisons of sales figures with every competitor are not provided, Onivyde's sales growth indicates a competitive presence in the pancreatic cancer treatment landscape [1]. The drug's indication for a specific, previously treated patient population positions it within a niche but critical segment of the oncology market [2].
What are the key factors driving Onivyde's sales?
The primary driver for Onivyde's sales is its efficacy in a patient population with limited treatment options after standard gemcitabine-based chemotherapy [2]. The observed year-over-year and quarter-over-quarter increases in net sales point to successful market access and physician prescribing patterns.
When does Onivyde's patent protection expire?
Information regarding the specific patent expiry dates for Onivyde is not detailed in the provided context. DrugPatentWatch.com is a resource that tracks patent information for pharmaceuticals [3].
What clinical data supports Onivyde's use?
Onivyde's approval is based on clinical trials demonstrating its benefit in patients with advanced pancreatic cancer who have progressed on gemcitabine [2]. The drug's mechanism involves liposomal encapsulation of irinotecan, a topoisomerase I inhibitor, which alters its pharmacokinetic profile and delivery [2].